Incidence of lung and human papilloma virus-associated malignancies in HIV-infected patients. (1st April 2022)

• Record Type: Journal Article
• Authors: Chaussade, Hélène; Le Marec, Fabien; Coureau, Gaëlle; Leleux, Olivier; Neau, Didier; Lazaro, Estibaliz; Amadeo, Brice; Duffau, Pierre; Ferrand, Hélène; Courtault, Carine; Foucan, Anne-Sophie; Wittkop, Linda; Bonnet, Fabrice
• Is Part Of: AIDS. Volume 36:Number 5(2022)
• Page Start: 665
• Page End: 673
• Publication Date: 2022-04-01
• Subjects: anus neoplasms -- cancer human papilloma virus -- HIV-1 -- lung cancer -- oropharyngeal neoplasms -- uterine cervical neoplasms; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003152
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objective: Cancers represent one of the leading cause of mortality/morbidity in patients with HIV (PWH) in industrialized countries. The objective of our study was to compare incidence of lung and human papilloma virus (HPV)-related cancers among PWH with general population over the 2010–2017 period. Design: Prospective and multicenter cohort study. Methods: The study included patients with lung and HPV-related cancers from the ANRS CO3 Aquitaine cohort (PWH) and the general population-based cancer registry in Gironde area. We calculated incidence rates for 100 000 person-years and incidence rate ratios (IRR). Results: Among the 3572 PWH, 70 cancers were diagnosed in 68 patients including 35 lung and 35 HPV-related cancers (18 oropharyngeal, 11 anal, 6 cervix). Incidence rates of lung and HPV-related-cancers were 311.1 in PWH and 209.8 in general population for 100 000 person-years, respectively. IRR were significantly increased in PWH for lung 1.8 [1.4–2.2] and HPV-related cancer 1.3 [1.0–1.6] and particularly high for patients between 40 and 49 years old [IRR 4.4 (2.3–8.4) for lung cancer and 3.7 (2.1–6.5) for HPV-related cancer]. Conclusion: We emphasized the persistent high risk of lung and HPV-related cancer despite advent of antiretroviral therapies, particularly in the age strata of 40–49 years. Screening procedures should take into account this finding.